Skip to main content
Clinical Trials/NL-OMON47404
NL-OMON47404
Completed
Phase 4

Prospective longitudinal outcome study assessing the use of REGENOSS for attaining spinal fusion in patients requiring single level Posterior Interbody Fusion (PLIF) in the lumbar spine. - REGENOSS posterior interbody fusion, pilot study

Finceramica0 sites24 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Finceramica
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Finceramica

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who signed the ethics committee approved specific informed consent prior to surgery.
  • 2\. Male and non\-pregnant female patients between 18\-70 years of age.
  • 3\. Patients with a BMI \<\<\= 35 Kg/m2
  • 4\. Patients with low\-grade spondylolisthesis requiring single\-level or 2 level posterior interbody fusion at level L3\-L4 L4\-L5 or L5\-S1\.
  • 5\. Patients who are physically and mentally willing and able to comply with postoperative functional evaluation.
  • 6\. Patient can read and understand the Dutch language.
  • 7\. If intra\-operatively the surgeons decided to fuse an additional level for spinal stability this is not an exclusion criteria however the primary level for surgical indication will be measured.

Exclusion Criteria

  • 1\. Patients who are unwilling to cooperate with the study protocol and follow\-up schedule.
  • 2\. Patients who, as judged by the surgeon, are mentally incompetent or are likely to be non\-compliant with the prescribed post\-operative routine and follow\-up evaluation schedule.
  • 3\. Patients with bleeding history, hemophelia or systemic blood diseases
  • 4\. Female patients that are pregnant or planning a pregnancy during the course of the study
  • 5\. Obese patients where obesity is severe enough to affect subject\*s ability to perform activities of daily living (body mass index, kg/m2 \> 35\)
  • 6\. Patients with active or suspected infection
  • 7\. Patients with malignancy \* active malignancy within last 5 years
  • 8\. Patients known with a diagnosed systemic disease that would affect the subject\*s welfare or overall outcome of the study (severe osteoporosis requiring medication, Paget\*s disease, renal osteodystrophy,hypercalcemia ) or is immunologically suppressed, or receiving steroids in excess of physiologic dose.
  • 9\. Patients with a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device or the patient has a neurological deficit which interferes with the patient\*s ability to limit weight bearing or places an extreme load on the implant during the healing period.
  • 10\. Patients with systemic or metabolic disorders leading to progressive bone deterioration

Outcomes

Primary Outcomes

Not specified

Similar Trials